



PRESS RELEASE

February 2, 2018
Fuji Pharma Co., Ltd.

**Agreement Reached to Make Fuji Pharma the Sole Distributor of
OYPALOMIN® Injection, IOPAQUE® Injection and
MEGLUMINE GADOPENTETATE Intravenous Solution “F”**

Fuji Pharma Co., Ltd. (Head office: Chiyoda-ku, Tokyo) has reached an agreement with KONICA MINOLTA JAPAN, INC. (Head office: Minato-ku, Tokyo) that makes Fuji Pharma the sole distributor of three products that have until now been sold jointly by the two companies in Japan. The products are OYPALOMIN® injection (Generic name: iopamidol), a non-ionic urinary tract and angiographic agent, IOPAQUE® injection (Generic name: iohexol), a non-ionic contrast media, and MEGLUMINE GADOPENTETATE intravenous solution “F” (Generic name: meglumine gadopentetate), a linear MRI contrast agent.

Konica Minolta will stop selling these three products once this company’s inventories of these items are sold out. Fuji Pharma will then be the sole provider of sales, distribution and information services for the three products.

Fuji Pharma received regulatory approval to manufacture and sell OYPALOMIN® injection in July 1996, IOPAQUE® injection in July 2001 and MEGLUMINE GADOPENTETATE intravenous solution “F” in November 2008. These products have been sold by Fuji Pharma and Konica Minolta with medical representatives providing information to support sales activities.

Fuji Pharma has the goal of making its contrast agent business even stronger while adapting with flexibility to the rapid changes taking place in Japan’s health care sector. To help accomplish this goal, Fuji Pharma held discussions with Konica Minolta that resulted in the agreement for Konica Minolta to stop selling the three contrast agents so that Fuji Pharma, the manufacturer, can be the sole distributor.

Fuji Pharma and Konica Minolta will cooperate to complete the transfer of sales rights quickly and prevent any disruption in the supply of products and the provision of associated information.

The effect of this change on consolidated results of operations for the fiscal year ending September 30, 2018 is insignificant.